Investor desk
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ISPOR 2026.
← Back to Events
Tier 1 Global Networking: High CARDIOLOGY CONCLUDED
ISPOR 2026 — Hyatt Regency Orlando, Philadelphia, USA
Leading international conference featuring poster presentations and exhibits on pharmacoeconomics and clinical research.
5,000+ Attendees
2 Presentations
1 Companies
Presentation data updated Jun 11, 2026, 5:32 AM UTC
Why This Event Matters
Leading international conference featuring poster presentations and exhibits on pharmacoeconomics and clinical research.
Industry impact
Leading international conference featuring poster presentations and exhibits on pharmacoeconomics and clinical research..
Market implications
Expect signals on pricing, formulary strategy, and partnership economics relevant to cardiology markets in the US region.
Regulatory implications
FDA and CMS policy discussions around evidence generation, 340B, and real-world data often surface at cardiology leadership forums.
Investor implications
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ISPOR 2026.
Competitive implications
Competitive positioning among top cardiology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Event Significance
Tier-1 industry catalyst
62 /100 composite
ISPOR 2026 is a targeted cardiology forum where specialty pipeline readouts and BD conversations drive near-term positioning decisions. Primary driver: downstream media and analyst follow-through.
- Media coverage 20/20
High follow-on media and sell-side note volume expected within 24–48h of key sessions.
- Speaker quality 20/20
Plenary and late-breaker slots attract global KOLs — high signal for clinical and regulatory teams.
- Pipeline relevance 0/20
Early science or services-focused — lower near-term PDUFA linkage.
- Historical influence 20/20
Prior editions moved stock prices and label expansions — expect similar volatility windows.
- Company participation 2/20
Smaller exhibitor set — focus on disclosed presenters rather than floor traffic.
Nova Pharma Intelligence · Analyst desk
Key Takeaways
- ImmunityBio carries 1 tracked presentations — map against peer readouts at ISPOR 2026.
- Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ISPOR 2026.
- FDA and CMS policy discussions around evidence generation, 340B, and real-world data often surface at cardiology leadership forums.
Timeline & Milestones
- Pre-event intelligence Complete
2 presentations tracked — Key Data and Companies hubs live.
- Conference opens May 17, 2026 Complete
Live readouts, late-breakers, and partnership announcements.
- Live coverage window Complete
2 Nova articles linked — see Coverage & Analysis.
- Conference closes May 20, 2026 Complete
Post-event recap, competitive takeaways, and trial updates.
Investors & analysts
Executive Summary
C-level briefLeading international conference featuring poster presentations and exhibits on pharmacoeconomics and clinical research.
Primary audience: Investors & analysts
Analyst Watch
Regulatory affairs
FDA and CMS policy discussions around evidence generation, 340B, and real-world data often surface at cardiology leadership forums.
Competitive intelligence
Competitive positioning among top cardiology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
vs. Prior Editions
| Edition | Presentations | Companies |
|---|---|---|
| ISPOR 2026 (current) | 2 | 1 |
| ISPOR 2026 International (2026) | 1 | 0 |
Most Anticipated Presentations
Full data hub → ORAL May 21
Lessons from More Than 30 Trial Emulations: Prospective Prediction of Results from Real-World Evidence Studies
POSTER
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
Competitive Landscape
Company map →Competitive positioning among top cardiology players and adjacent technology vendors is a core theme — compare outcomes with prior editions and peer conferences.
Companies to Watch
All companies →Coverage & Analysis
2 articlesRelated News & Research
Research hub →Event Intelligence Summary
Standalone summaries for ISPOR 2026 — optimized for research and AI retrieval.
Executive Summary
Leading international conference featuring poster presentations and exhibits on pharmacoeconomics and clinical research.
Analyst View
Leading international conference featuring poster presentations and exhibits on pharmacoeconomics and clinical research..
Investor View
Investors should track partnership announcements, pipeline prioritization signals, and vendor consolidation themes emerging from ISPOR 2026.
BD View
BD teams should prioritize networking with presenting companies and services vendors at ISPOR 2026, focusing on cardiology partnership and licensing opportunities.
Key Facts
- Event
- ISPOR 2026
- Focus
- cardiology
- Region
- US Americas
- Attendance
- 5,000+
Ask Nova AI
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Frequently Asked Questions
What is ISPOR 2026?
ISPOR 2026 is a cardiology industry conference bringing together executives, clinical leaders, and investors to discuss pipeline, regulatory, and commercial strategy.
Who attends ISPOR 2026?
Typical attendees include pharma executives, BD teams, investors, regulatory affairs professionals, and clinical operations leaders focused on cardiology.
Why is ISPOR 2026 important?
ISPOR 2026 influences partnership timing, pipeline prioritization, and policy debates that affect cardiology markets for the next 12–18 months.
When is ISPOR 2026?
ISPOR 2026 takes place on the scheduled dates.
Where is ISPOR 2026 held?
ISPOR 2026 is held in the listed venue.
How many attendees does ISPOR 2026 attract?
ISPOR 2026 typically draws 5,000+ attendees from across the cardiology ecosystem.
What companies participate at ISPOR 2026?
1+ companies present data or participate in programming at ISPOR 2026, spanning large pharma, biotech, and services vendors.
What should investors watch at ISPOR 2026?
Investors should track partnership announcements, pipeline readouts, M&A signals, and management commentary on cardiology catalysts during and after ISPOR 2026.
What BD opportunities exist at ISPOR 2026?
BD teams use ISPOR 2026 for licensing discussions, co-development talks, and vendor selection across cardiology — especially in networking sessions and satellite meetings.
How does ISPOR 2026 compare with other pharma conferences?
ISPOR 2026 is a tier-1 global congress for cardiology — compare speaker quality, company participation, and historical deal flow with peer events in the same therapeutic or commercial vertical.
How do I get NovaPharmaNews coverage of ISPOR 2026?
NovaPharmaNews publishes pre-event briefs, live coverage, and post-event analysis for ISPOR 2026. Subscribe to event alerts on this page for breaking updates.